Euclidean Capital
VC Fund
New York, United States
Euclidean Capital is an investment firm that invests in individual and family services management.
- Total investments:
- 70
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Euclidean Capital invests in
Stages Euclidean Capital invests in
Countries Euclidean Capital invests in
Round sizes
Round size
- Series A
- $21M–$85M
- Series B
- $21M–$185M
- Series C
- $46M–$120M
Investment Focus
Industry
- Biotechnology 20 (29%)
- Health Care 15 (21%)
- Medical 10 (14%)
- Therapeutics 10 (14%)
- FinTech 6 (9%)
Stage
- Series B 17 (24%)
- Series A 14 (20%)
- Series C 12 (17%)
- Series E 5 (7%)
- Funding Round 5 (7%)
Country
- United States 33 (47%)
- India 2 (3%)
- Sweden 1 (1%)
- Australia 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $92.5M / Series E / Sep 16, 2026 | ||
| Savvy Wealth is a technology-enabled wealth management firm that provides a digital-first platform for financial advisors centered around optimizing human financial advice. With this platform, financial advisors utilize its purpose-built, integrated technology platform to help build organic growth with enhanced software and sales and marketingautomation. | $100M / Series C / Sep 09, 2026 | ||
| Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 17, 2026 | ||
| InduPro is a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies. | $77M / Series B / Aug 12, 2026 | ||
| Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M / Series B / Jun 22, 2026 | ||
| Ripple Foods specializes in making non-dairy milk with just as much protein as milk and half the sugar. Ripple has 8x the protein of almond milk and half the sugar of dairy milk. It’s high in bioavailable calcium (50% more than milk), potassium and provides a good source of omega-3s. It’s lower in calories than milk and best of all, it has thecreamy, delicious texture our dairy-free friends are missing. No more thin, chalky almond/ soy/ cashew milk.It was founded in 2014 and headquartered in Emeryville, California. | $17M / Dec 02, 2025 | ||
| Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 27, 2025 | ||
| SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $115M / Series D / Aug 11, 2025 | ||
| April has developed a tax platform that simplifies the filing process for U.S. taxpayers and enables better financial planning. | $38M / Series B / Jul 23, 2025 | ||
| Savvy Wealth is a technology-enabled wealth management firm that provides a digital-first platform for financial advisors centered around optimizing human financial advice. With this platform, financial advisors utilize its purpose-built, integrated technology platform to help build organic growth with enhanced software and sales and marketingautomation. | $72M / Series B / Jul 02, 2025 | ||
| See all 70 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Euclidean Capital invest in?
Euclidean Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 70 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Euclidean Capital's check size?
Euclidean Capital typically joins rounds of $21M–$85M at Series A, $21M–$185M at Series B and $46M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Euclidean Capital participates in.
When did Euclidean Capital last invest?
The most recent investment recorded for Euclidean Capital closed in Sep 2026. Shizune tracks 70 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
